Development of CD96 antibodies for cancer treatment [ 2015 - 2017 ]

Research Grant

Researchers: Prof Mark Smyth (Principal investigator) ,  A/Pr John Miles

Brief description There is an unmet medical need to develop new immunotherapies that are safer and potentially allow the treatment of a broader range of cancers. Inhibiting the immune checkpoint CD96 function represents an opportunity that may parallel and indeed complement the activity and impact of other lymphocyte checkpoint inhibitors in human cancer (eg. CTLA-4 and PD1/PD-L1). While developing a new human therapeutic antibody we will also learn more about an important checkpoint in the immune response.

Funding Amount $AUD 820,821.59

Funding Scheme Development Grants

Notes Development Grant